Connect. Influence. Grow.

Sanat Chattopadhyay is responsible for the company’s (approx.  $64 billion revenue) worldwide manufacturing and supply operations across a global network of sites for pharmaceuticals, vaccines, biologics and animal health products. Merck is known as MSD outside of the U.S. and Canada.

Sanat joined Merck in 2009 as Senior Vice President of Global Vaccines & Sterile Manufacturing Operations, spearheading the transformation of manufacturing and supply chain to grow and globalize its Vaccine business. Under Sanat’s leadership, Merck is currently executing a significant expansion of its biologics and vaccines manufacturing capacity with planned capital investments of more than $20 billion from 2020 through the end of 2024, to reach more patients around the globe.

Before joining Merck, he served as Senior Vice President, Technical Operations & Product Supply, for Wyeth Pharmaceuticals. Previously, he worked at Aventis and its predecessor companies as Senior Vice President, Industrial Operations, having served in many positions with increasing responsibilities for global supply chain, technology and manufacturing sites across North America, Europe and Asia Pacific. Sanat started his career with Hoechst Pharmaceuticals in 1983 and worked in many senior leadership assignments.

Sanat is a graduate in Chemical Engineering and holds a post-graduate degree in Industrial Engineering from India.

Outside of Merck, Sanat is a member of the Board of Directors of Ashland Inc.

Hilary Marston, M.D., M.P.H. is a Principal at Canal Row Advisors, a regulatory strategy consulting firm. Prior to this, Dr. Marston served as the Chief Medical Officer of the FDA. She oversaw clinical matters that involved multiple product development centers, including financial incentives for rare disease product development, combination product jurisdiction and research participant protection policy. She also led Agency response to health crises, including epidemics and shortages.

Dr. Marston previously served as Senior Advisor for Global COVID-19 Response on the White House COVID Team, Director for Medical Biopreparedness and Response at the National Security Council, and Policy Advisor for Pandemic Preparedness at the National Institutes of Health.

Dr. Marston trained in Internal Medicine at Brigham & Women’s Hospital.

Scott Gottlieb, MD, is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration. He is currently a senior fellow at the American Enterprise Institute for Public Policy Research and a partner at the venture capital firm New Enterprise Associates.

Under his leadership, the FDA advanced new frameworks for the modern oversight of gene therapies, cell-based medicines, and digital health devices. The agency implemented new reforms to standardize drug reviews and made historic improvements in post-market data collection and the use of real-world evidence. He promoted policies to reduce death and disease from tobacco, improve food safety, and aggressively confront addiction crises. The agency’s prolific advances in new policy distinguished his tenure as FDA Commissioner, along with a record-setting number of approvals for novel drugs, medical devices, and generic medicines.

Previously, Dr. Gottlieb served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs and, before that, as a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services. He is the author of the New York Times bestselling book “Uncontrolled Spread: Why Covid-19 Crushed Us and How We Can Defeat the Next Pandemic” and is a regular contributor to CNBC and CBS News’ Face the Nation. Dr. Gottlieb serves on the board of directors of publicly traded companies Pfizer, Inc., Illumina, Inc., and TempusAI.

Dr. Gottlieb is an elected member of the National Academy of Medicine and completed medical school and a residency in internal medicine at the Mount Sinai School of Medicine, where he currently serves on the executive committee of the Mount Sinai Health System’s board of directors and co-chairs the board’s education committee. He graduated from Wesleyan University, where he majored in economics, and currently serves on the university’s board of directors. Dr. Gottlieb lives in Connecticut with his wife and three daughters.

Kimberly has achieved several first-in-industry achievements throughout her career within life sciences. Currently at Johnson & Johnson Innovative Medicine, she shapes the long-term vision, strategic direction and execution of end-to-end supply chains and global manufacturing networks for emerging new modalities, including cell & gene therapy and radio pharmaceuticals.

Before joining J&J, Kimberly served as SVP, Global Supply Chain at Bristol Myers Squibb, where she oversaw plan, deliver, digital excellence and integrated product strategies for all commercial products in addition to plan for all clinical supplies. Under Kimberly’s leadership, the global supply team successfully launched more than nine new products, including several within hours of FDA approval,
and BMS was recognized on the annual ‘Supply Chain Top 25’ list by Gartner. Both achievements were firsts in the company’s history.

Earlier in her career at Novartis, Kimberly led the supply chain teams that achieved FDA approval and launch for the world’s first CD-19 CAR-T therapy and launched the first FDA-approved biosimilar.
Kimberly received her M.B.A. from the Wharton School, University of Pennsylvania and her B.S in Chemical Engineering from Northwestern University. She has been recognized as one of the Fierce Pharma’s ’20 Fiercest Women in Life Sciences’.

Kimberly serves on the Advisory Board of the Department of Chemical and Biological Engineering at Northwestern University and is passionate about mentoring tomorrow’s workforce to excel in STEM careers.

Tina Self is a dynamic leader with over 20 years of experience in the biotech and pharmaceutical industries, specializing in quality and manufacturing. Currently, she serves as the Senior Vice President of Global Biologics Manufacturing and Berkeley Site Head at Bayer. Tina has been with Bayer for over eight years, where she has held several key leadership roles, including Vice President of Manufacturing Operations and Vice President of Quality. She is recognized for her strategic oversight of manufacturing processes, commitment to quality assurance, and her ability to drive continuous improvement. Tina holds an MS in Biotechnology from The Johns Hopkins University and an MBA in International Business from Florida Atlantic University.